The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
Open accessAbstract
PURPOSE: The objective of this study was to estimate the risk of contralateral breast cancer in BRCA1 and BRCA2 carriers; and measure the extent to which host, family history, and cancer treatment-related factors modify the risk. PATIENTS AND METHODS: Patients were 810 women, with stage I or II breast cancer, for whom a BRCA1 or BRCA2 mutation had been identified in the family. Patients were followed from the initial diagnosis of cancer until contralateral mastectomy, contralateral breast cancer, death, or last follow-up. RESULTS: Overall, 149 subjects (18.4%) developed a contralateral breast cancer. The 15-year actuarial risk of contralateral breast cancer was 36.1% for women with a BRCA1 mutation and was 28.5% for women with a BRCA2 mutation. Women younger than 50 years of age at the time of breast cancer diagnosis were significantly more likely to develop a contralateral breast cancer at 15 years, compared with those older than 50 years (37.6 vs 16.8%; P=0.003). Women aged <50 years with two or more first-degree relatives with early-onset breast cancer were at high risk of contralateral breast cancer, compared with women with fewer, or no first-degree relatives with breast cancer (50 vs 36%; P=0.005). The risk of contralateral breast cancer was reduced with oophorectomy (RR 0.47; 95% CI 0.30-0.76; P=0.002). CONCLUSION: The risk of contralateral breast cancer risk in BRCA mutation carriers declines with the age of diagnosis and increases with the number of first-degree relatives affected with breast cancer. Oophorectomy reduces the risk of contralateral breast cancer in young women with a BRCA mutation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We observed that family history is a predictor of CBC risk in both noncarriers and mutation carriers, which is in line with previous literature.19,21”
From Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers (2016) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ford, D., Easton, D., Stratton, M. R., Narod, S., Goldgar, D., Devilee, P., Bishop, D., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · American Journal of Human Genetics · doi:10.1086/301749 · Cited by 2,766
Self-citationRebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn442 · Cited by 939
Self-citationContralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Metcalfe, K. A., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I. A., Warner, E., Olopade, O. I., Eisen, A. F., Weber, B., McLennan, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.033 · Cited by 620 · cited 1×
“…lifetime risk of breast cancer (Ford et al, 1998) and, once diagnosed with breast cancer, face a high risk of second primary cancer in the contralateral breast (Robson et al, 1998; Verhoog et al, 1998, 2000; Haffty et al, 2002; Metcalfe et al, 2004; Brekelmans et al, 2007; Graeser et al, 2009).”
BackgroundSelf-citationSurvival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07065-7 · Cited by 452 · cited 1×
“…lifetime risk of breast cancer (Ford et al, 1998) and, once diagnosed with breast cancer, face a high risk of second primary cancer in the contralateral breast (Robson et al, 1998; Verhoog et al, 1998, 2000; Haffty et al, 2002; Metcalfe et al, 2004; Brekelmans et al, 2007; Graeser et al, 2009).”
BackgroundEisen, A. F., Lubiński, J., Klijn, J. G. M., Møller, P., Lynch, H. T., Offit, K., Weber, B., Rebbeck, T., Neuhausen, S. L., Ghadirian, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.7138 · Cited by 442
Self-citationContralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Graeser, M. K., Engel, C., Rhiem, K., Gadzicki, D., Bick, U., Kast, K., Froster, U. G., Schlehe, B., Bechtold, A., Arnold, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9430 · Cited by 314 · cited 1×
“…lifetime risk of breast cancer (Ford et al, 1998) and, once diagnosed with breast cancer, face a high risk of second primary cancer in the contralateral breast (Robson et al, 1998; Verhoog et al, 1998, 2000; Haffty et al, 2002; Metcalfe et al, 2004; Brekelmans et al, 2007; Graeser et al, 2009).”
BackgroundOutcome of conservatively managed early-onset breast cancer by BRCA1/2 status
Haffty, B. G., Harrold, E., Khan, A. J., Pathare, P., Smith, T. E., Turner, B. C., Glazer, P. M., Ward, B., Carter, D., Matloff, E., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08434-9 · Cited by 307 · cited 1×
“…lifetime risk of breast cancer (Ford et al, 1998) and, once diagnosed with breast cancer, face a high risk of second primary cancer in the contralateral breast (Robson et al, 1998; Verhoog et al, 1998, 2000; Haffty et al, 2002; Metcalfe et al, 2004; Brekelmans et al, 2007; Graeser et al, 2009).”
BackgroundBRCA-associated breast cancer in young women.
Robson, M. E., Gilewski, T., Haas, B. R., Levin, D. R., Borgen, P. I., Rajan, P., Hirschaut, Y., Pressman, P., Rosen, P. P., LESSER, M. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1642 · Cited by 303 · cited 1×
“…lifetime risk of breast cancer (Ford et al, 1998) and, once diagnosed with breast cancer, face a high risk of second primary cancer in the contralateral breast (Robson et al, 1998; Verhoog et al, 1998, 2000; Haffty et al, 2002; Metcalfe et al, 2004; Brekelmans et al, 2007; Graeser et al, 2009).”
BackgroundTamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update
Gronwald, J., Tung, N., Foulkes, W. D., Offit, K., Gershoni, R., Daly, M. B., Kim‐Sing, C., Olsson, H. L., Ainsworth, P., Eisen, A. F., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21536 · Cited by 253
Self-citationBrekelmans, C. T. M., Tilanus-Linthorst, M. M. A., Seynaeve, C., vd Ouweland, A., Menke-Pluymers, M. B. E., Bartels, C. C. M., Kriege, M., van Geel, A. N., Burger, C. W., Eggermont, A. M. M., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.12.009 · Cited by 233 · cited 1×
“…lifetime risk of breast cancer (Ford et al, 1998) and, once diagnosed with breast cancer, face a high risk of second primary cancer in the contralateral breast (Robson et al, 1998; Verhoog et al, 1998, 2000; Haffty et al, 2002; Metcalfe et al, 2004; Brekelmans et al, 2007; Graeser et al, 2009).”
Background
Flagged first, then by citations
Cited by
Sorted by citations
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K.-A., Mooij, T. M., Roos-Blom, M.-J., Jervis, S., van Leeuwen, F. E., Milne, R. L., Andrieu, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7112 · Cited by 2,954
Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., Evans, D. G., Izatt, L., Eeles, R. A., Adlard, J., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt095 · Cited by 951
Tung, N., Boughey, J. C., Pierce, L. J., Robson, M. E., Bedrosian, I., Dietz, J. R., Dragun, A. J., Balmañà, J., Hofstatter, E. W., Isaacs, C. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00299 · Cited by 335
Self-citationSecond Malignant Neoplasms: Assessment and Strategies for Risk Reduction
Wood, M. E., Vogel, V. G., Ng, A. K., Foxhall, L. E., Goodwin, P. J., & Travis, L. B. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.8681 · Cited by 325
“Mutations in BRCA1 and BRCA2 are associated with high risks of second primary breast cancer or ovarian cancer.(11,12) Mutations in mismatch repair genes (MLH1, MSH2, PMS1, MSH6) confer an increased risk of a variety of cancers including second primary colon cancers, other gastrointestinal and gynecologic cancers.”
BackgroundMetcalfe, K. A., Gershman, S., Ghadirian, P., Lynch, H. T., Snyder, C., Tung, N., Kim‐Sing, C., Eisen, A. F., Foulkes, W. D., Rosen, B. P., et al. (2014) · BMJ · doi:10.1136/bmj.g226 · Cited by 311
Self-citationCardoso, F., Loibl, S., Pagani, O., Graziottin, A., Panizza, P., Martincich, L., Gentilini, O., Peccatori, F. A., Fourquet, A., Delaloge, S., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.10.004 · Cited by 314
Yoshida, R. (2020) · Breast Cancer · doi:10.1007/s12282-020-01148-2 · Cited by 331
Risk-reducing mastectomy for the prevention of primary breast cancer
Carbine, N. E., Lostumbo, L., Wallace, J., & Ko, H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002748.pub4 · Cited by 270
Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline
Bedrosian, I., Somerfield, M. R., Achatz, M. I., Boughey, J. C., Curigliano, G., Friedman, S., Kohlmann, W. K., Kurian, A. W., Laronga, C., Lynce, F., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02225 · Cited by 216
Bilateral Oophorectomy and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers
Kotsopoulos, J., Huzarski, T., Gronwald, J., Singer, C. F., Møller, P., Lynch, H. T., Armel, S. R., Karlan, B. Y., Foulkes, W. D., Neuhausen, S. L., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw177 · Cited by 197
“Also, among BRCA carriers with a previous diagnosis of breast cancer, oophorectomy statistically significantly reduces breast cancer mortality and decreases the risk of contralateral breast cancer (6,7).”
Self-citationContralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer
Evans, D. G. R., Ingham, S. L., Baildam, A., Ross, G. L., Lalloo, F., Buchan, I., & Howell, A. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2583-1 · Cited by 178
“and 60 % at 20 years of follow-up) [1–4].”
BackgroundInfluentialValachis, A., Nearchou, A. D., & Lind, P. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2890-1 · Cited by 182
“However, we were unable to quantify this relation due to the differences in the use of age as variable among studies [11, 14] as well as the lack of multivariable analysis in three studies [24, 29, 31].”
BackgroundMethodYadav, S., Boddicker, N. J., Na, J., Polley, E. C., Hu, C., Hart, S. N., Gnanaolivu, R. D., Larson, N. L., Holtegaard, S., Huang, H., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01239 · Cited by 175
“2-fold increased risk of CBC and the 15-year cumulative incidence of approximately 30% and 25% for CBC after an initial breast cancer diagnosis for BRCA1 and BRCA2 PV carriers, respectively, are consistent with previous studies.(6,27-31) Althoughprevious studies focused predominantly on CBC risks in high-risk women qu…”
ResultSelf-citationTamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Phillips, K.-A., Milne, R. L., Rookus, M. A., Daly, M. B., Antoniou, A. C., Peock, S., Frost, D., Easton, D. F., Ellis, S., Friedlander, M. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.8313 · Cited by 171
Harbeck, N., Scharl, A. J., Thomssen, C., & Müller, V. (2013) · Breast Care · doi:10.1159/000353590 · Cited by 146
Rhiem, K., Engel, C., Graeser, M., Zachariae, S., Kast, K., Kiechle, M. B., Ditsch, N. C., Janni, W. J., Mundhenke, C., Golatta, M., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3369 · Cited by 128
“Estimates for contralateral breast cancer range from 15% to 40% within 10 years [1,3,5-10].”
BackgroundMethodInfluentialReiner, A. S., John, E. M., Brooks, J. D., Lynch, C. F., Bernstein, L., Mellemkjær, L., Malone, K. E., Knight, J. A., Capanu, M., Teraoka, S. N., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2013 · Cited by 113
van den Broek, A. J., van ’t Veer, L. J., Hooning, M. J., Cornelissen, S., Broeks, A., Rutgers, E. J., Smit, V. T. H. B. M., Cornelisse, C. J., van Beek, M., Janssen-Heijnen, M. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3942 · Cited by 104
BRCA Mutations and Breast Cancer Prevention
Kotsopoulos, J. (2018) · Cancers · doi:10.3390/cancers10120524 · Cited by 104
“Once diagnosed with invasive breast cancer, these women have a high risk of developing a second ipsilateral [5] or contralateral breast cancer [6].”
BackgroundCragun, D. L., Bonner, D. E., Kim, J., Akbari, M. R., Narod, S. A., Gomez-Fuego, A., García, J., Vadaparampil, S. T., & Pal, T. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3374-7 · Cited by 102
“Identifying breast cancer survivors who are BRCA carriers, empowers them with options to substantially reduce their high risk for a second primary breast cancer [9] as well as their 20–40 % lifetime risk for ovarian cancer [7, 8, 10, 11].”
Self-citationMolina‐Montes, E., Perez-Nevot, B., Pollán, M., Sánchez‐Cantalejo, E., Espín, J., & Sánchez, M. (2014) · The Breast · doi:10.1016/j.breast.2014.10.005 · Cited by 91
“2011 [16] at <50 years at first BC 5 e e e e 14.”
BackgroundResultInfluentialRisk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers
Metcalfe, K. A., Lynch, H. T., Ghadirian, P., Tung, N., Kim‐Sing, C., Olopade, O. I., Domchek, S. M., Eisen, A. F., Foulkes, W. D., Rosen, B. P., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1336-7 · Cited by 82
Self-citationBellavance, E. C., & Kesmodel, S. B. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00074 · Cited by 82
Bernstein, J. L., Thomas, D. C., Shore, R. E., Robson, M. E., Boice, J. D., Stovall, M. A., Andersson, M., Bernstein, L., Malone, K. E., Reiner, A. S., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.028 · Cited by 81
“Among BRCA/BRCA2 gene mutation carriers, estimates of lifetime risk of developing a first primary breast cancer range from 26%-84% (8-10) and about 22%-60% for developing asynchronous CBC (9, 11-15).”
BackgroundResultDisparities in Genetic Testing and Care Among Black Women with Hereditary Breast Cancer
Reid, S., Cadiz, S., & Pal, T. (2020) · Current Breast Cancer Reports · doi:10.1007/s12609-020-00364-1 · Cited by 74
Sheppard, V. B., Graves, K. D., Christopher, J., Hurtado‐de‐Mendoza, A., Talley, C. H., & Williams, K. P. (2013) · Journal of Genetic Counseling · doi:10.1007/s10897-013-9663-6 · Cited by 73
“…diagnosed with the disease or family members with multiple cases of breast cancer and/or both breast and ovarian cancer; (c) a high incidence of contralateral breast cancer in young (≤50 years) Black women; and (d) association with other malignancies (Metcalfe et al. 2011; Newman et al. 2006).”
BackgroundNarod, S. A. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.3 · Cited by 72
Self-citationBreast Cancer Risks and Risk Prediction Models
Engel, C., & Fischer, C. (2015) · Breast Care · doi:10.1159/000376600 · Cited by 68
Review of risk factors for the development of contralateral breast cancer
Lizarraga, I. M., Sugg, S. L., Weigel, R. J., & Scott‐Conner, C. E. H. (2013) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2013.08.002 · Cited by 65
“Prophylactic oophorectomy is thought to reduce CBC risk by half.(32)”
BackgroundDrooger, J. C., Hooning, M. J., Seynaeve, C., Baaijens, M. H. A., Obdeijn, I. M., Sleijfer, S., & Jager, A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.002 · Cited by 64
Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis
Akdeniz, D., Schmidt, M. K., Seynaeve, C., McCool, D., Giardiello, D., van den Broek, A. J., Hauptmann, M., Steyerberg, E. W., & Hooning, M. J. (2018) · The Breast · doi:10.1016/j.breast.2018.11.005 · Cited by 57
“Seven papers reported on risk factors in both BRCA1 and BRCA2 mutation carriers [3,15,33,40,53,59,80], and one in BRCA1mutation carriers only [2].”
BackgroundBlondeaux, E., Sonnenblick, A., Agostinetto, E., Bas, R., Kim, H. J., Franzoi, M. A., Bernstein‐Molho, R., Linn, S. C., Kwong, A., Pogoda, K., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00152-4 · Cited by 58
Challenging and Complex Decisions in the Management of the BRCA Mutation Carrier
Stan, D. L., Shuster, L. T., Wick, M. J., Swanson, C. L., Pruthi, S., & Bakkum-Gamez, J. N. (2013) · Journal of Women s Health · doi:10.1089/jwh.2013.4407 · Cited by 60
“50,51 Long-term follow-up will be critical to a full understanding of the late medical consequences and psychological impact of RRSO.”
InfluentialPan, B., Xu, Y., Zhou, Y., Yao, R., Wu, H., Zhu, Q., Wang, C., Mao, F., Lin, Y., Shen, S., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2198 · Cited by 58
Fanale, D., Incorvaia, L., Filorizzo, C., Bono, M., Fiorino, A., Calò, V., Brando, C., Corsini, L. R., Barraco, N., Badalamenti, G., et al. (2020) · Cancers · doi:10.3390/cancers12092415 · Cited by 57
“5%, but increases by up to 3% in BRCA1 or BRCA2 PV carriers, increasing 10-year cumulative risk up to 13–40% [1,12,13].”
BackgroundSoran, A., Polat, A. K., Johnson, R. R., & McGuire, K. P. (2014) · The Surgeon · doi:10.1016/j.surge.2014.02.005 · Cited by 55
Engel, C., Fischer, C., Zachariae, S., Bucksch, K., Rhiem, K., Giesecke, J., Herold, N., Wappenschmidt, B., Hübbel, V., Maringa, M., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32396 · Cited by 54
The role of body size and physical activity on the risk of breast cancer in BRCA mutation carriers
Pettapiece-Phillips, R., Narod, S. A., & Kotsopoulos, J. (2015) · Cancer Causes & Control · doi:10.1007/s10552-014-0521-0 · Cited by 52
“Women with BRCA-associated breast cancers are diagnosed typically at a young age (30–50 years of age) [5] and have a high risk of developing contralateral [6] or ipsilateral breast cancer [7].”
BackgroundSelf-citationBerliner, J. L., Cummings, S. A., Burnett, B. B., & Ricker, C. N. (2021) · Journal of Genetic Counseling · doi:10.1002/jgc4.1374 · Cited by 55
“These studies have shown that as age at diagnosis decreases, risk for a contralateral breast cancer increases (Kuchenbaecker et al., 2017; Menes et al., 2015; Metcalfe et al., 2011; Molina-Montes et al., 2014).”
BRCA mutation genetic testing implications in the United States
Bayraktar, S., & Arun, B. (2016) · The Breast · doi:10.1016/j.breast.2016.11.021 · Cited by 51
Management of hereditary breast and ovarian cancer
Yamauchi, H., & Takei, J. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1208-9 · Cited by 55
Contralateral risk-reducing mastectomy in sporadic breast cancer
Murphy, J. A., Milner, T. D., & OʼDonoghue, J. M. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70047-0 · Cited by 47
Gaba, F., & Manchanda, R. (2020) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2020.01.006 · Cited by 46
Pal, T., & Vadaparampil, S. T. (2012) · Cancer Control · doi:10.1177/107327481201900402 · Cited by 44
Gronwald, J., Robidoux, A., Kim‐Sing, C., Tung, N., Lynch, H. T., Foulkes, W. D., Manoukian, S., Ainsworth, P., Neuhausen, S. L., Demsky, R., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3026-3 · Cited by 44
“The lifetime risk of breast cancer in a woman who carries a deleterious mutation in BRCA1 or BRCA2 is approximately 80 % [1] and following an initial diagnosis of breast cancer the annual risk of contralateral breast cancer is approximately 3 % [2].”
InfluentialSelf-citationThe Business Impact Of Social Media Analytics
Kurniawati, K., Shanks, G., & Bekmamedova, N. (2013) · European Conference on Information Systems · Cited by 43
Contralateral Prophylactic Mastectomy: Challenging Considerations for the Surgeon
Angelos, P., Bedrosian, I., Euhus, D., Herrmann, V. M., Katz, S. J., & Pusic, A. L. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4758-y · Cited by 42
“Similarly, the number and age of affected family members have an impact on the CBC risk for a BRCA mutation carrier.(3) Among women who are not BRCA mutation carriers, age-based risk varies with family history.”
BackgroundDifferences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location
Sekine, M., Nishino, K., & Enomoto, T. (2021) · Genes · doi:10.3390/genes12071050 · Cited by 40
Patterns of Occurrence and Outcomes of Contralateral Breast Cancer: Analysis of SEER Data
Xiong, Z., Yang, L., Deng, G., Huang, X., Li, X., Xie, X., Wang, J., Shuang, Z., & Wang, X. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7060133 · Cited by 37
Menes, T. S., Terry, M. B., Goldgar, D. E., Andrulis, I. L., Knight, J. A., John, E. M., Liao, Y., Southey, M. C., Miron, A., Chung, W. K., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3419-y · Cited by 39
“Metcalfe [20], using data from a multicenter cohort of BRCA carrier families, reported an association with the number of first degree relatives affected with breast cancer.”
BackgroundMethodTumor characteristics and prognosis in familial breast cancer
Arpino, G., Pensabene, M., Condello, C., Ruocco, R., Cerillo, I., Lauria, R., Forestieri, V., Giuliano, M., Angelis, C. D., Montella, M., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2962-1 · Cited by 39
“Several studies have shown that contralateral breast cancer risk in familial non-BRCA-mutated breast cancer patients varies depending on the patient’s age at the first breast cancer diagnosis [42, 48, 54].”
BackgroundSemple, J. L., Metcalfe, K. A., Lynch, H. T., Kim‐Sing, C., Senter, L. A., Pal, T., Ainsworth, P., Lubiński, J., Tung, N., Eng, C., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3040-4 · Cited by 37
Self-citationReiner, A. S., Robson, M. E., Mellemkjær, L., Tischkowitz, M. D., John, E. M., Lynch, C. F., Brooks, J. D., Boice, J. D., Knight, J. A., Teraoka, S. N., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa031 · Cited by 36
“Our findings extend prior but smaller, less comprehensive studies reporting no demonstrable elevated CBC risk among BRCA1/2 mutation carriers treated with RT (10,11).”
ResultLakeman, I. M. M., van den Broek, A. J., Vos, J. A. M., Barnes, D. R., Adlard, J., Andrulis, I. L., Arason, A., Arnold, N., Arun, B. K., Balmañà, J., et al. (2021) · Genetics in Medicine · doi:10.1038/s41436-021-01198-7 · Cited by 36
Self-citationFreitas, V., Li, X., Amitai, Y., Au, F. W.-F., Kulkarni, S. R., Ghai, S., Mulligan, A. M., Bromley, M., & Siepmann, T. (2022) · Radiology · doi:10.1148/radiol.212361 · Cited by 35
Drooger, J. C., Akdeniz, D., Pignol, J., Koppert, L. B., McCool, D., Seynaeve, C., Hooning, M. J., & Jager, A. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3597-7 · Cited by 34
Choi, Y., Terry, M. B., Daly, M. B., MacInnis, R. J., Hopper, J. L., Colonna, S. V., Buys, S. S., Andrulis, I. L., John, E. M., Kurian, A. W., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.7995 · Cited by 34
Prophylactic Surgery: For Whom, When and How
Mau, C. Y., & Untch, M. (2017) · Breast Care · doi:10.1159/000485830 · Cited by 33
Genetic Predisposition Syndromes and Their Management
Euhus, D., & Robinson, L. D. (2013) · Surgical Clinics of North America · doi:10.1016/j.suc.2013.01.005 · Cited by 36
Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
Kotsopoulos, J., Singer, C., & Narod, S. A. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4029-z · Cited by 37
Self-citationBRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers
Sun, J., Chu, F., Pan, J., Zhang, Y., Yao, L., Chen, J., Hu, L., Zhang, J., Xu, Y., Wang, X., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00833 · Cited by 31
for the TFGT Collaborative Group, Watts, K., Meiser, B., Mitchell, G., Kirk, J., Saunders, C. M., Peate, M., Duffy, J., Kelly, P. J., Gleeson, M., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-320 · Cited by 31
“Compared with noncarriers, BRCA1 and BRCA2 mutation carriers have a substantially increased lifetime risk of contralateral breast cancer that is age dependent and can be up to 68%, if the age of the first cancer is <40 [3,4].”
BackgroundKharazmi, E., Chen, T., Narod, S. A., Sundquist, K., & Hemminki, K. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2848-3 · Cited by 30
“An increased contralateral breast cancer risk with decreasing age at diagnosis of the first cancer and with family history of breast cancer has been shown previously [24].”
BackgroundSelf-citationHasson, S. P., Menes, T. S., & Sonnenblick, A. (2020) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s233485 · Cited by 28
Genetic testing and familial implications in breast-ovarian cancer families
Oosterwijk, J. C., de Vries, J., Mourits, M. J. E., & de Bock, G. H. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.05.002 · Cited by 28
Folate and breast cancer: what about high-risk women?
Kotsopoulos, J., Kim, Y., & Narod, S. A. (2012) · Cancer Causes & Control · doi:10.1007/s10552-012-0022-y · Cited by 27
“Women with BRCA-associated breast cancers are diagnosed at a young age (typically between ages 30 and 50 years) [121], have an elevated risk of developing contralateral [122] or ipsilateral breast cancer [123], and exhibit pathological characteristics suggestive of an aggressive phenotype (e.”
BackgroundSelf-citationPrevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With Breast Cancer
Abulkhair, O. A. M., Balwi, M. A. A., Makram, O., Alsubaie, L., Faris, M., Shehata, H., Hashim, A., Arun, B., Saadeddin, A., & Ibrahim, E. M. (2018) · Journal of Global Oncology · doi:10.1200/jgo.18.00066 · Cited by 26
Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing
Murphy, B. L., Yi, M., Arun, B., Gutierrez‐Barrera, A. M., & Bedrosian, I. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08889-6 · Cited by 26
Shubeck, S. P., Sevilimedu, V., Berger, E. R., Robson, M. E., Heerdt, A. S., & Pilewskie, M. L. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11756-1 · Cited by 25
“Additionally, the risk of developing a contralateral breast cancer event was higher for women less than 50 years of age at the time of their index breast cancer diagnosis.(15) Our data similarly show a relatively high rate of contralateral breast cancer among women undergoing unilateral breast surgery, with 10-year ra…”
BackgroundKwong, A., & Chu, A. T.-W. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.5.2241 · Cited by 24
“Prophylactic mastectomy rate (including completion mastectomy and contralateral prophylactic mastectomy) was found to be about 20% overall in all mutation carriers, which is in the mid range compared with that of international studies (Metcalfe et al., 2011).”
ResultKorea Breast Cancer Study Group, Noh, J. M., Choi, D. H., Nam, S. J., Lee, J. E., Kim, J., Kim, S., Kang, E., Lee, M. H., Ahn, S. H., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1718-5 · Cited by 24
“published study [30].”
BackgroundAkdeniz, D., van Barele, M., Heemskerk‐Gerritsen, B. A. M., Steyerberg, E. W., Hauptmann, M., van de Beek, I., van Engelen, K., Wevers, M. R., Gómez-García, E. B., Ausems, M. G. E. M., et al. (2021) · The Breast · doi:10.1016/j.breast.2021.12.007 · Cited by 23
“So far, the effects of chemotherapy on CBC risk in BRCA1/2 mutation carriers have been investigated only in a limited number of studies [1,10,11]; in only one study the effects of different chemotherapeutic agents on CBC risk were investigated, though with BRCA1 and BRCA2 mutation carriers combined [11].”
BackgroundAn Overview of Hereditary Breast and Ovarian Cancer Syndrome
Smith, E. C. (2012) · Journal of Midwifery & Women s Health · doi:10.1111/j.1542-2011.2012.00199.x · Cited by 25
BRCA1 mRNA levels following a 4–6-week intervention with oral 3,3′-diindolylmethane
Kotsopoulos, J., Zhang, S., Akbari, M., Salmena, L., Llacuachaqui, M., Zeligs, M., Sun, P., & Narod, S. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.391 · Cited by 24
“Women with BRCA-associated breast cancers are often diagnosed at a young age (Narod, 2010), and have elevated risks of developing contralateral (Metcalfe et al, 2011a) and ipsilateral breast cancer (Metcalfe et al, 2011b).”
BackgroundSelf-citationTrombetta, M. G., Dragun, A. J., Mayr, N. A., & Pierce, L. J. (2020) · Practical Radiation Oncology · doi:10.1016/j.prro.2020.04.003 · Cited by 23
Contralateral Risk-Reducing Mastectomy: Review of Risk Factors and Risk-Reducing Strategies
Basu, N., Barr, L. C., Ross, G. L., & Evans, D. G. (2015) · International Journal of Surgical Oncology · doi:10.1155/2015/901046 · Cited by 22
“Risk-reducing bilateral salpingo-oophorectomy (RRBSO) and menopause before the age of 40 [8, 10, 11] are protective factors.”
BackgroundAdemuyiwa, F. O., Salyer, P., Ma, Y., Fisher, S. L., Colditz, G. A., Weilbaecher, K. N., & Bierut, L. J. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05359-w · Cited by 22
Su, L., Xu, Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., & Xie, Y. (2020) · International Journal of Cancer · doi:10.1002/ijc.32918 · Cited by 22
Ayme, A., Viassolo, V., Rapiti, E., Fioretta, G., Schubert, H., Bouchardy, C., Chappuis, P., & Benhamou, S. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2864-3 · Cited by 25
Metcalfe, K. A., Eisen, A. F., Poll, A., Candib, A., McCready, D. R., Cil, T. D., Wright, F. C., Demsky, R., Mancuso, T., Sun, P., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09855-6 · Cited by 21
Self-citationWang, F., Amara, D., Peled, A. W., Sbitany, H., Foster, R. D., Ewing, C. A., Alvarado, M. D., & Esserman, L. J. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4745-3 · Cited by 21
Lim, K. K., Yoon, S. Y., Taib, N. A. M., Shabaruddin, F. H., Dahlui, M., Woo, Y. L., Thong, M., Teo, S., & Chaiyakunapruk, N. (2018) · Applied Health Economics and Health Policy · doi:10.1007/s40258-018-0384-8 · Cited by 22
“Subsequently, all patients entered the Markov model with six health states: ipsilateral breast cancer (IBC, recurrence or new primary breast cancer in the same breast), contralateral breast cancer (CBC, new breast cancer in the opposite breast), ovarian cancer (OC), at risk of IBC, CBC and/or OC (depending on the choi…”
MethodInfluentialYoon, T. I., Kwak, B. S., Yi, O. V., Kim, S., Um, E., Yun, K. W., Shin, H.-N., Lee, S.-B., Sohn, G., Chung, I. Y., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-5031-4 · Cited by 20
Jia, Z., Li, J., Zhang, Y., Wang, X., Xing, Z., Xing, Z., Huang, X., Liu, G., Zhang, M., Feng, K., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02194-2 · Cited by 20
Gaba, F., Blyuss, O. B., Tan, A., Munblit, D., Oxley, S. G., Khan, K. S., Legood, R., & Manchanda, R. (2023) · Cancers · doi:10.3390/cancers15051625 · Cited by 21
“Studies investigating CBC adjusted for age [64], menopause [66], ascertainment [66], mutation status [64] and BC treatment (chemotherapy/radiotherapy/surgery/tamoxifen) [63,64].”
Disparities in contralateral prophylactic mastectomy use among women with early-stage breast cancer
Kim, Y., McCarthy, A. M., Bristol, M. N., & Armstrong, K. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0004-z · Cited by 20
Metcalfe, K. A., Retrouvey, H., Kerrebijn, I., Butler, K., O’Neill, A. C., Cil, T. D., Zhong, T., Hofer, S. O. P., & McCready, D. R. (2019) · Cancer · doi:10.1002/cncr.32405 · Cited by 20
Self-citationQureshi, N., Dutton, B., Weng, S. F., Sheehan, C., Chorley, W., Robertson, J. F. R., Kendrick, D., & Kai, J. (2020) · Familial Cancer · doi:10.1007/s10689-020-00188-z · Cited by 19
de Groot, J. S., Moelans, C. B., Elias, S. G., Hennink, A., Verolme, B., Suijkerbuijk, K. P. M., Jager, A., Seynaeve, C., Bos, P. G., Witkamp, A. J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127895 · Cited by 19
“This risk is estimated to be 20–60% or even higher and is influenced by various factors such as age at diagnosis and adjuvant systemic therapy [5,6].”
BackgroundPathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections
Fountzilas, E., Konstantopoulou, I., Vagena, A., Apostolou, P., PAPADIMITRIOU, C. A., Christodoulou, C., Tryfonopoulos, D. J., Manousou, K., Delimitsou, A., Papamentzelopoulou, M., et al. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.08.003 · Cited by 19
Hallam, S., Govindarajulu, S., Huckett, B., & Bahl, A. K. (2015) · Clinical Oncology · doi:10.1016/j.clon.2015.06.001 · Cited by 21
Metcalfe, K. A., Eisen, A. F., Poll, A., Candib, A., McCready, D. R., Cil, T. D., Wright, F. C., Lerner‐Ellis, J. P., McCuaig, J. M., Graham, T., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09160-8 · Cited by 18
Self-citationLim, D. W., Retrouvey, H., Kerrebijn, I., Butler, K., O’Neill, A. C., Cil, T. D., Zhong, T., Hofer, S. O. P., McCready, D. R., & Metcalfe, K. A. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09928-6 · Cited by 17
Self-citationOophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers
Kotsopoulos, J., Lubiński, J., Lynch, H. T., Tung, N., Armel, S. R., Senter, L. A., Singer, C. F., Fruscio, R., Couch, F. J., Weitzel, J. N., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05162-7 · Cited by 17
Self-citationrs15869 at miRNA binding site in BRCA2 is associated with breast cancer susceptibility
Cao, J., Luo, C., Yan, R., Peng, R., Wang, K., Wang, P., Ye, H., & Song, C. (2016) · Medical Oncology · doi:10.1007/s12032-016-0849-2 · Cited by 16
“Recent studies reported that reproductive factors influences breast cancer risk in women with a BRCA1 or BRCA2 mutations [21, 22].”
BackgroundHereditary Breast and Ovarian Cancer
Bellcross, C. A. (2022) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2021.11.005 · Cited by 16
Wevers, M. R., Schmidt, M. K., Engelhardt, E. G., Verhoef, S., Hooning, M. J., Kriege, M., Seynaeve, C., Collee, M. J., van Asperen, C. J., Tollenaar, R. A. �. �., et al. (2015) · Familial Cancer · doi:10.1007/s10689-015-9788-x · Cited by 16
“Once diagnosed with unilateral breast cancer, BRCA1/2 mutation carriers have a 16–55 % risk of developing contralateral breast cancer within 25 years, depending on, among other factors, age at first diagnosis and the mutated gene [3, 4].”
Li, Z., Fadare, O., Hameed, O., Zhao, C., & Desouki, M. M. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.08.010 · Cited by 16
Apostolova, C., Ferroum, A., Alhassan, B., Prakash, I., Basik, M., Boileau, J. F., Martel, K., Meterissian, S. H., Villareal-Corpuz, V., Wong, N., et al. (2024) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2024.108324 · Cited by 19
Self-citationAn Overview on Radiation Sensitivity in Hereditary Breast and Ovarian Cancer Syndrome
Gonçalves, D., Pires, A. S., Marques, I. A., Gomes, I., Sousa, G., Botelho, M. F., & Abrantes, A. M. (2022) · Cancers · doi:10.3390/cancers14133254 · Cited by 15
“Thus, it is concluded that the risk of developing contralateral breast cancer decreases with the age of BRCA mutation carriers at the time of diagnosis and with the performance of oophorectomy, increasing, in turn, with the number of first-degree relatives with the same diagnosis [52].”
Background
Metadata
- Authors
- Metcalfe, K., Gershman, S., Lynch, H. T., Ghadirian, P., Tung, N., Kim-Sing, C., Olopade, O. I., Domchek, S., McLennan, J., Eisen, A., Foulkes, W. D., Rosen, B., Sun, P., & Narod, S. A.
- Affiliations
- University of Toronto (CA)
- Creighton University (US)
- Centre Hospitalier de l’Université de Montréal (CA)
- Beth Israel Deaconess Medical Center (US)
- University of Chicago (US)
- University of Pennsylvania (US)
- University of California, San Francisco (US)
- Sunnybrook Health Science Centre (CA)
- McGill University (CA)
- University Health Network (CA)
- Women’s College Hospital Research and Innovation Institute (CA)
- Corresponding author
- Narod, S A
- Venue
- British Journal of Cancer
- Published
- 2011-04
- Volume
- 104
- Issue
- 9
- Pages
- 1384-1392
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC3101934
- OpenAlex
- W2002561481
- Cited by
- 232
- References
- 15
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 12 · 2023: 11 · 2022: 15 · 2021: 21 · 2020: 31 · 2019: 13 · 2018: 9 · 2017: 12 · 2016: 17 · 2015: 20 · 2014: 18 · 2013: 21 · 2012: 16
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Keywords
- contralateral breast cancer, BRCA1 mutation, BRCA2 mutation, hereditary breast cancer, oophorectomy, age at diagnosis, family history (medicine), first-degree relatives, early-onset breast cancer, risk factors, young women
- MeSH terms
- Adult, Age Factors, Aged, Breast Neoplasms, Female, Heterozygote, Humans, Middle Aged, Mutation, Ovariectomy, Predictive Value of Tests, Risk Factors, Cohort Studies, Odds Ratio, Survival Analysis, Neoplasms, Second Primary, Risk Assessment, Genes, BRCA1, Genetic Predisposition to Disease, Genes, BRCA2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
